Dr Lal PathLabs June quarter net profit declines 52% to Rs 28.4 crore

Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.

Dr Lal PathLabs June quarter net profit declines 52% to Rs 28.4 crore
Press Trust of India New Delhi
1 min read Last Updated : Jul 31 2020 | 5:32 PM IST

Diagnostic services provider Dr Lal PathLabs on Friday reported a 51.94 per cent decline in its consolidated net profit at Rs 28.4 crore for the quarter ended June 30, 2020.

The company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing to BSE.

Consolidated revenue from operations of the company stood at Rs 266 crore, as against Rs 335.2 crore in the year-ago period, it said adding that underlying patient volume decline was 28.4 per cent during the quarter.

"This was a difficult quarter, not just for Dr Lal Pathlabs, but for the entire nation and the economy. Business was impacted adversely, with volumes getting hit.

"However, we are confident of things returning to normal and the business performance getting back on track in some time post normalization," Dr Lal PathLabs Executive Chairman Arvind Lal said.

Shares of Dr Lal PathLabs closed at Rs1,888.85per scrip on BSE, up 0.41 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Dr Lal PathLabsIndian companiesDiagnostics

First Published: Jul 31 2020 | 5:17 PM IST

Next Story